WebMD

Romvimza for Tenosynovial Giant Cell Tumor (TGCT)

Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor (TGCT) that may be made worse by surgery. TGCT is a condition where tumors form in joints of the ...
mskcc.org

FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumor (TGCT)

Dr. William Tap led the development of vimseltinib for tenosynovial giant cell tumor. The U.S. Food and Drug Administration (FDA) has approved vimseltinib (Romvimza TM) for adult patients with a rare ...
Business Wire

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S ...
Business Wire

U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell ...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the U.S. Food and Drug Administration ...
Cure Today

Emactuzumab Gets Fast Track Designation in Tenosynovial Giant Cell Tumors

Emactuzumab has received FDA fast track designation for TGCT treatment, aiding development for conditions lacking effective options. The phase 3 TANGENT trial evaluates emactuzumab, a CSF-1R ...
New York Post

I had a one-in-a-million tumor eating my bones — the signs that made me beg doctors to see me

A Los Angeles woman says she was put off by doctors' offices when she tried to get help for her leg pain. Nejron Photo - stock.adobe.com A 37-year-old woman says that if she hadn’t doggedly called ...
WebMD

Your Guide to Turalio for Tenosynovial Giant Cell Tumor

Tenosynovial giant cell tumor (TGCT) is a group of rare tumors. They are usually benign (not cancer) and tend to occur in people between 25 to 50 years old. The tumors affect areas of the joints and ...
Medscape

EMA Recommends Romvimza for Tenosynovial Giant Cell Tumor

At its July 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization in the European Union for Romvimza ...
BioWorld

Deciphera’s Romvimza wins FDA nod for tenosynovial giant cell tumors

Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral CSF1R inhibitor vimseltinib, newly branded Romvimza, could take significant ...
mskcc.org

A Revolutionary Bone Implant Saves a Patient’s Leg Decades After Giant Cell Tumor

MSK orthopedic surgeon Dr. Jonathan Forsberg examines Michelle Smith-Levitin’s leg at a follow-up appointment — a first-of-its-kind surgical implant saved her leg. The tennis court was Michelle ...
Medscape

FDA Approves Vimseltinib for Tenosynovial Giant Cell Tumors

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult patients with symptomatic tenosynovial giant cell tumors (TGCT) who will not ...